10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Period	Debt/Equity
2019-12-31	0.44
2020-12-31	0.26
2021-12-31	0.25
2022-12-31	0.28
2023-12-31	0.30
2024-12-31	0.29

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TXG	$22.04	-1.30%	1.21M
3
4
5

10x Genomics Inc. (TXG) Debt to Equity Ratio

Debt to Equity Ratio Data

Get 10x Genomics Inc. Data in Excel

More TXG Financial Data